Explore ›
Finding
Finding
improvement
The alemtuzumab-belatacept-sirolimus regimen promoted repopulation of a lymphocyte repertoire enriched for naive CD28+ T and B cells and depleted of differentiated CD28-negative effectors, with increased regulatory cell populations, creating conditions more favorable for belatacept's intended immunosuppressive effect.
| Follow-up | 18 months |
| Comparator | Pre-transplant lymphocyte repertoire of the same patients (paired comparison) |
| Effect summary | improvement |
Connected entities
Conditions
Source
PMC4642731
Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors